Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
15 hedge funds and large institutions have $11.9M invested in Kiromic BioPharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
257% more capital invested
Capital invested by funds: $3.34M → $11.9M (+$8.57M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
36% more funds holding
Funds holding: 11 → 15 (+4)
28.64% more ownership
Funds ownership: 4.87% → 33.51% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$6.41M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.18M |
| 3 |
ACM
Altium Capital Management
New York
|
+$2.79M |
| 4 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$1.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$910K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$252K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$203K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| 4 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$752 |
KRBP Hedge Fund Activity: Q2 2021 in Review
15 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q2 2021, worth a combined $11.9M — up 257% from $3.34M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KRBP positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $6.41M. The largest seller was Zeke Capital Advisors, cutting an estimated $252K.
- 15 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q2 2021, up from 11 in Q1 2021.
- Funds reported $11.9M of Kiromic BioPharma, Inc. Common Stock stock for Q2 2021, up 257% quarter-over-quarter.
- 7 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of +4 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q2 2021 was Kepos Capital, an estimated $6.41M added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q2 2021 was Zeke Capital Advisors, an estimated $252K sold.
Based on aggregated 13F filings for Q2 2021.